Tsiporah B. Shore, M.D.

Medical Oncology
Tsiporah Shore

Dr. Shore is an expert in stem cell / bone marrow transplantation, with over 20 years of experience in this field. She is the Associate Director of the Blood and Bone Marrow Transplant Program of New York Presbyterian Hospital - Cornell. She has major interests in improving the overall safety and effectiveness of transplantation. Dr. Shore is also very experienced in the management of hematological malignancies such as leukemia, lymphoma, myeloma, myelodysplasia, as well as aplastic anemia. Dr Shore teaches residents and fellows management of patients undergoing transplantation and has published articles in this field. She also reviews articles for medical journals relating to stem cell transplantation.

Dr. Shore is also an expert in the field of melanoma. She is a member of the New York City Melanoma Consortium, conducting clinical trials in the therapy of early and late stage melanoma.

Dr. Shore is committed to providing the best possible, state of the art care for her patients, with clear explanations and ongoing personal support through difficult situations.

Dr. Tsiporah Shore is the Associate Director of the Bone Marrow and Stem Cell Transplantation Program in the Division of Hematology / Oncology of Weill Medical College of Cornell University and New York Presbyterian Hospital. She is an Associate Professor of Clinical Medicine at Weill Medical College. Dr. Shore graduated from medical school (1979) and did a residency at the University of Manitoba in Canada and the University of Toronto ( internship.) She then went on to complete a hematology / oncology fellowship at Tufts New England Medical Center in Boston. She did an additional 2 year subspecialty fellowship in Bone Marrow Transplantation in Seattle and Vancouver and subsequently developed and directed the Manitoba BMT Program, in Winnipeg, Canada from 1987 - 1999. Dr. Shore has extensive experience in the diagnosis and management of all hematological malignancies including leukemias, lymphomas, myeloma, and myelodysplastic/ myeloproliferative disorders. Dr. Shore also has a major interest in the management of malignant melanoma. She was the provincial representative to the National Cancer Institute of Canada on the Melanoma subcommittee and both conducted and participated in clinical trials in the area of melanoma. She is now a member of the New York Melanoma Consortium. In 1999, Dr. Shore relocated to New York and eventually joined the staff of Weill Medical College of Cornell University, with her practise located at New York Presbyterian Hospital. While Dr. Shore has experience in all facets of hematology and oncology, she is especially interested in continuing to advance the field of bone marrow / stem cell transplantation, malignant hematologic disorders and melanoma utilizing novel therapies and clinical trials in addition to standard therapies.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [PPO]
  • AETNA [HMO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Health Plan
  • CIGNA
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup
  • Medicare [Medicare]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Oxford Health Plans [Liberty]
  • Rockefeller University - CoreSource
  • United Empire
  • United Health Care [Medicare]
  • United Health Care
  • United Health Care [Community Plan]

Publications

Shepherd JD, Shore T, Reece DE, et al. Cyclosporine/Methylprednisone Prophylaxis for Acute Graft-Vs-Host Disease. Bone Marrow Transplantation in 1988; 3:553-558

Shore T, Eisenhauer E, Quirt I, Belanger K, Lohmann R, Silver H, Wielgosz G. A Phase II Study of DuP 937 (Teloxantrone) in Metastatic Malignant Melanoma: A Study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Short Report - Annals of Oncology 1993; 4:695-96

Couban Stephen, Simpson David R., Barnett Michael J, Bredeson Christopher, Hubesch Lothar, Howson – Jan Kang, Shore Tsiporah B., Walker Irwin R, Browett Peter, Messner Hans A., Panzarella Tony, Lipton Jeffrey H., for the Canadian Bone Marrow Transplant Group: A randomized multicenter ceomparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002 100: 1525 – 1531.

ShoreT, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT. A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy. Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75.

Shore T. Stem Cell Transplantation for Myelodysplastic Syndromes: The Lure of a Cure. Current Hematologic Malignancy Reports. 2007. Vol. 2, No. 7:3-8.

Honors and Awards

  • 1973 - 1974, University of Manitoba Dean's Honor List
  • Rosabelle Searle Leach Scholarship for Highest Standing    
       
  •              Isbister Undergraduate Scholarship for Highest Standing
                         
  • 1974 - 1975, University of Manitoba Dean's Honor List
  • University Women's Club of Winnipeg Undergraduate                   Scholarship for Highest Standing
  • Alumni Association Scholarship for High Standing
  • 1984-1985 Fellowship in Clinical Oncology of the National Cancer Institute             of Canada
  • 1989-1990 Most Outstanding Clinician by the Medicine IV Class (Honourable Mention) University of Manitoba
    li>1998    Manitoba Quality Network (QNET) Quality Champion Award